TESARO Announces Data Presentations at the 2019 SGO Annual Meeting on Women’s Cancer

    NEXT STORY
    Continued ICP Orders From Japanese Customers
    PREV STORY
    Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Operating and Financial Results
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

    author_avatar
    NASDAQ Market News

    Nanosphere Announces Record Preliminary Q4 and Full Year 2015 Results

    Preliminary Fourth Quarter Revenue of $6.8 MillionPreliminary Full Year Revenue of $21.0 Million Exceeding ...

    author_avatar
    NASDAQ Market News

    ThromboGenics Business Update – Q3 2017

    Press release                                                          20 October, 2017Regulated Information Diabetic Eye Disease programs progressing €53.7 million cash ...

    author_avatar
    NASDAQ Market News